PFKFB3 RNA expression varied with tumor subtype, indicating that a future inhibitory treatment may be more effective in the Luminal A and HER2 positive tumors than the in triple negative and Luminal B subtype. This evidence concerns the gene PFKFB3 and neoplasm.